白蛋白结合型紫杉醇联合奈达铂同步放疗治疗巨块型子宫颈癌的效果及安全性  

Efficacy and safety of albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy in tretment of massive cervical cancer

作　　者：王丽娜 王玉霞[1] 王乐[1] 靳红[1] 黄可金[1] 李奇[1] 成海燕[1] Wang Lina;Wang Yuxia;Wang Le;Jin Hong;Huang Kejin;Li Qi;Cheng Haiyan(Department of Gynecology Oncology,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院妇瘤科,哈尔滨150081

出　　处：《肿瘤研究与临床》2021年第6期419-422,共4页Cancer Research and Clinic

摘　　要：目的:探讨白蛋白结合型紫杉醇联合奈达铂同步放疗治疗Ⅲ期巨块型子宫颈癌的近期效果及安全性。方法:回顾性分析2019年4月至2020年4月哈尔滨医科大学附属肿瘤医院收治的84例巨块型子宫颈癌患者临床资料。患者依据不同治疗方案分为观察组和对照组,各42例。观察组采用白蛋白结合型紫杉醇联合奈达铂同步放疗,对照组采用溶剂型紫杉醇联合奈达铂同步放疗。比较两组近期疗效及不良反应。结果:观察组、对照组治疗1个月时部分缓解(PR)率分别为92.9%(39/42)、35.7%(15/42),差异有统计学意义(χ^(2)=29.867,P<0.01)。观察组、对照组治疗后1个月完全缓解(CR)率分别为59.5%(25/42)、38.1%(16/42),差异有统计学意义(χ^(2)=3.859,P=0.049)。观察组腹泻发生率为33.3%(14/42),低于对照组的54.8%(23/42),差异有统计学意义(χ^(2)=3.913,P=0.048);两组血液学不良反应及肝、肾功能异常发生率比较,差异均无统计学意义(均P>0.05)。结论:白蛋白结合型紫杉醇联合奈达铂同步放疗治疗Ⅲ期巨块型子宫颈癌的近期效果较好,不良反应可耐受。Objective To investigate the short-term efficacy and safety of albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy in treatment of stageⅢmassive cervical cancer.Methods The clinical data of 84 patients with massive cervical cancer admitted to Harbin Medical University Cancer Hospital from April 2019 to April 2020 were retrospectively analyzed.According to the different treatment regimens,patients were divided into the observation group and the control group,each with 42 cases.The observation group received albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy,and the control group received solvent-based paclitaxel combined with nedaplatin followed by concurrent radiotherapy.The short-term efficacy and adverse reactions of the two groups were compared.Results The partial remission(PR)rate of the observation group and the control group at 1 month of treatment was 92.9%(39/42)and 35.7%(15/42),respectively,and the difference was statistically significant(χ^(2)=29.867,P<0.01).The complete remission(CR)rate of the observation group and the control group at 1 month after treatment was 59.5%(25/42)and 38.1%(16/42),respectively,and the difference was statistically significant(χ^(2)=3.859,P=0.049).The incidence of diarrhea of the observation group was lower than that of the control group[33.33%(14/42)vs.54.8%(23/42)],and the difference was statistically significant(χ^(2)=3.913,P=0.048).There were no statistical differences in the incidence of hematological adverse reactions and abnormal liver and kidney functions between the two groups(all P>0.05).Conclusion The albumin-bound paclitaxel combined with nedaplatin followed by concurrent radiotherapy have a good short-term efficacy in treatment of stageⅢmassive cervical cancer,and the adverse reactions are tolerable.

关 键 词：宫颈肿瘤 白蛋白结合型紫杉醇 巨块型子宫颈癌 放射疗法 药物疗法 联合 

分 类 号：R737.33[医药卫生—肿瘤]